Literature DB >> 23420589

Therapeutic plasma exchange: a technical and operational review.

Andre A Kaplan1.   

Abstract

Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique designed for the removal of large molecular weight substances. Examples of these substances include pathogenic autoantibodies, immune complexes, cryoglobulins, myeloma light chains, endotoxin and cholesterol containing lipoproteins. The basic premise of the treatment is that removal of these substances will allow for the reversal of the pathologic processes related to their presence. This review will cover the techniques for performing TPE, the kinetics of the removal of large molecules from the plasma and the benefits and risks of the different types of replacement fluids.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23420589     DOI: 10.1002/jca.21257

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  32 in total

Review 1.  Principles of separation: indications and therapeutic targets for plasma exchange.

Authors:  Mark E Williams; Rasheed A Balogun
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-31       Impact factor: 8.237

Review 2.  Effects of therapeutic plasma exchange on anticoagulants in patients receiving therapeutic anticoagulation: a systematic review.

Authors:  Kimberly L Hodulik; Adam G Root; Leila S Ledbetter; Oluwatoyosi A Onwuemene
Journal:  Transfusion       Date:  2019-02-14       Impact factor: 3.157

3.  Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

Authors:  Tadeusz Robak; Maciej Kaźmierczak; Isidro Jarque; Vasile Musteata; Jacek Treliński; Nichola Cooper; Peter Kiessling; Ute Massow; Franz Woltering; Rose Snipes; Juan Ke; Grant Langdon; James B Bussel; Stephen Jolles
Journal:  Blood Adv       Date:  2020-09-08

Review 4.  The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals.

Authors:  William M Baldwin; Anna Valujskikh; Robert L Fairchild
Journal:  Am J Transplant       Date:  2019-04-15       Impact factor: 8.086

5.  Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology.

Authors:  Andrew J B Watts; Keith H Keller; Gabriel Lerner; Ivy Rosales; A Bernard Collins; Miroslav Sekulic; Sushrut S Waikar; Anil Chandraker; Leonardo V Riella; Mariam P Alexander; Jonathan P Troost; Junbo Chen; Damian Fermin; Jennifer L Yee; Matthew G Sampson; Laurence H Beck; Joel M Henderson; Anna Greka; Helmut G Rennke; Astrid Weins
Journal:  J Am Soc Nephrol       Date:  2021-11-03       Impact factor: 10.121

6.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

7.  Rapidly progressive course of pauci-immune pulmonary capillaritis in a 70-year-old Asian male refractory to immunosuppression and plasma exchange.

Authors:  Chuan Jiang; Grace Nabila Martinez Pena; Meng Xie; Khalid Gafoor
Journal:  BMJ Case Rep       Date:  2020-03-12

Review 8.  Therapeutic Plasma Exchange Using Membrane Plasma Separation.

Authors:  Sadiq Ahmed; Andre Kaplan
Journal:  Clin J Am Soc Nephrol       Date:  2020-04-20       Impact factor: 8.237

9.  Outcome of therapeutic plasma exchange in Myasthenia gravis patients.

Authors:  Ashu Dogra; Kaushik Rana; Chirag Rathod; Sanjay Prakash
Journal:  J Family Med Prim Care       Date:  2020-12-31

10.  Treatment of MuSK-Associated Myasthenia Gravis.

Authors:  Khalid El-Salem; Ahmed Yassin; Kefah Al-Hayk; Salma Yahya; Duha Al-Shorafat; Said S Dahbour
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.